Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Aug 14 · above the Ichimoku cloud · RSI 47 · MACD below its signal
| 9.19 | Previous month high | +46.49% |
| 9.19 | 52-week high | +46.49% |
| 7.65 | Previous week high | +22.01% |
| 7.16 | R3 (classic) | +14.27% |
| 6.98 | R2 (classic) | +11.36% |
| 6.80 | Previous day high | +8.44% |
| 6.63 | R1 (classic) | +5.68% |
| 6.44 | Pivot | +2.76% |
| 6.27 | Price now | |
| 6.26 | Previous day low | −0.16% |
| 6.09 | S1 (classic) | −2.92% |
| 5.90 | S2 (classic) | −5.84% |
| 5.70 | Previous week low | −9.09% |
| 5.55 | S3 (classic) | −11.52% |
| 4.27 | Previous month low | −31.90% |
| 2.80 | 52-week low | −55.34% |
None of the 29 investors followed here reported a position in NTRB in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NTRB trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for NTRB.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.5 | -7.3 | -20.5 | 9.5 | -9.7 | -8.6 | -10.7 | 53.2 | 72.2 | -16.6 | +38.1% | ||
| 2025 | 76.0 | -12.3 | -15.7 | 12.2 | -5.5 | 21.1 | -8.4 | -10.3 | 9.0 | -4.5 | -26.5 | -8.2 | −3.6% |
| 2024 | 12.5 | -3.1 | 78.7 | -23.5 | 57.5 | -0.9 | 11.3 | -32.1 | 48.3 | 2.3 | -22.5 | -1.9 | +103.0% |
| 2023 | 1.2 | 9.3 | -17.0 | 0.6 | -14.7 | 5.7 | 30.0 | -17.7 | -20.6 | -11.8 | 12.4 | -8.3 | −35.6% |
| 2022 | -56.6 | -11.0 | 8.2 | -6.2 | 18.7 | -12.4 | 24.6 | -12.3 | -6.8 | 19.2 | -8.4 | -8.0 | −58.3% |
| 2021 | 2.6 | 57.0 | +61.0% |
Buy / hold / sell counts
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.